ArticleJMIR research protocols2020

Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial.

Shinobu Shimizu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.